Now I have sufficient grounding. Let me write the consolidated review.

---

## Summary

This paper proposes HypoGeneAgent, an LLM-driven framework that uses the consistency of LLM-generated GO annotations to guide cluster resolution selection in single-cell/Perturb-seq data. An LLM agent (configured through extensive Stage 1 benchmarks) generates ranked GO hypotheses for each cluster; from these, intra-cluster agreement (ICS) and inter-cluster distinctiveness (ICD) are computed and combined into a Resolution Score. Applied to K562 Perturb-seq data, the score peaks at resolution 0.4 (GEX) and 0.5 (perturbation). The idea of using functional annotation consistency as a resolution criterion is novel and well-motivated.

## Strengths

1. **Novel and well-motivated idea.** Using LLM-generated annotation consistency to select clustering resolution is genuinely creative and addresses a real gap in single-cell analysis — resolution choice currently relies on generic statistical indices or subjective manual inspection. The pipeline architecture (cluster → LLM annotation → consistency score → resolution selection) is clean and principled.

2. **Well-executed Stage 1 ablation establishing the LLM configuration.** The paper systematically benchmarks five LLM backends (GPT-4o, GPT-o3, GPT-5, Gemini-2.0-flash, Gemini-2.5-pro), three embedding methods (OpenAI, SapBERT, Nomic AI), prompt variants, and temperature sweeps on 100 curated GOBP gene sets. The conclusion that GPT-o3 + hypothesis prompt yields the best annotation accuracy is empirically grounded (Fig. S1, S2, S3), and the agent's top-1 candidates show the highest cosine similarity with ground truth (Fig. S1d, AUC = 0.743 at threshold 0.40).

3. **Application at both GEX and perturbation levels.** The framework is applied to two levels of the same K562 dataset, producing Resolution Score peaks at 0.4 and 0.5 respectively, with qualitatively coherent cluster structures in UMAP (Figures 3b, 4b). This dual-level consistency suggests the approach generalizes across data representations.

## Weaknesses

### Major

1. **The central claim — that the Resolution Score selects a *biologically better* resolution — is not supported by quantitative evidence.** The paper shows that different metrics (silhouette, modularity, enrichment analysis) select somewhat different resolutions and that HypoGeneAgent chooses 0.4/0.5, but it never evaluates which resolution actually recovers known biological structure better. The K562 Perturb-seq dataset (Replogle et al.) contains guide RNAs targeting specific genes with known pathway roles — a proper evaluation would quantify how well each resolution's clusters recapitulate known pathway memberships (via ARI or NMI against a known grouping). Without this, the paper's headline claim ("compared to classical metrics," from the abstract) is asserted, not demonstrated. The closest thing to validation is the enrichment analysis agreement (Section 4.4.3), which applies the same ICS/ICD framework to enrichment p-values — this shows self-consistency, not independent biological validation.

2. **No negative controls to establish that the Resolution Score captures *data structure* rather than *LLM properties*.** The ICS and ICD (Eq. 1) are computed entirely from the LLM's own outputs, with no comparison to ground truth. A high Resolution Score could reflect the LLM reusing similar language for related clusters, or an intrinsically narrow output distribution. A basic control — applying the same pipeline to randomly shuffled gene lists or uniform random clusters to check that the score does not produce a clear peak — is absent. Until such controls exist, the metric's sensitivity to real biological partitions over arbitrary ones is unestablished.

3. **The comparison with traditional metrics is descriptive, not comparative.** Figures 3–5 show that silhouette, modularity, and the Resolution Score select different resolutions. But the paper never measures which selection is *better* on any objective, quantifiable axis. The implied claim of superiority is unsupported — the paper documents disagreement among methods but provides no evidence that HypoGeneAgent's choice is the correct one.

### Minor

1. **The weight w = 1/3 in the Resolution Score is weakly justified.** The paper states it "was chosen by a small grid search and found to give a stable ordering of resolutions across data sets" (Section 3.4) but does not report the grid search details, the range tested, or what "stability" means quantitatively. Different w values could affect the optimal resolution (Fig. S5 is mentioned but not discussed in terms of sensitivity).

2. **No statistical significance tests.** The box plots in Figures 3–4 show the Resolution Score distribution at each resolution, but there is no pairwise test (e.g., Wilcoxon) confirming that the score at the selected resolution is significantly higher than at adjacent resolutions.

3. **No analysis of stochasticity.** The Leiden clustering algorithm is stochastic, but the paper does not report whether the optimal resolution is stable across random seeds or runs.

## Nice-to-Haves

- A quantitative comparison table showing ARI/NMI of clusters at each resolution against known pathway groupings (for both HypoGeneAgent and traditional metrics) would directly address the central weakness.
- A negative control experiment (shuffled gene lists, uniform random data) to demonstrate the metric's specificity.
- Reporting API cost / runtime would support the "computationally efficient" claim.
- A brief discussion of how LLM hallucination rates could affect the Resolution Score.

## Removed Points

- **Criticism about "overstated claims of objectivity"** (Harsh Critic point 4): This is a philosophical critique of the term "objective," not a substantive methodological weakness. The paper uses "objective" to mean "systematic and automated," which is reasonable in context. Removed.

- **Strength Finder claim 1 ("outperforms generic indices")**: The paper does not demonstrate outperformance — it shows disagreement among methods. Retaining this as stated would be misleading. The strength has been reframed as "novel and well-motivated idea" instead.

- **Strength Finder claim about "dual validation demonstrates generalizability"**: "Generalizability" overstates what two resolutions on one dataset show. Reframed as a more modest observation about dual-level consistency.

- **Harsh Critic point about w=1/3 being "vague"**: This is a genuine issue but is not a fundamental flaw; it is re-categorized as Minor rather than Major, since a sensitivity analysis (Fig. S5) exists.

- **Strength Finder generic praise** (e.g., "this paper addressed an important problem"): Removed as superficial — every paper at a venue like ICLR addresses an important problem.

- **Strength Finder's claim about "evidence establishes that the agent's self-verification and confidence ranking are trustworthy"**: Overstated. The AUC of 0.743 at threshold 0.40 shows moderate correlation, not strong trustworthiness. Retained but toned down in the strength description.

- **Harsh Critic's point about the paper "overpromises" in the introduction**: This is a presentation nitpick rather than a substance issue. Removed.

## Novel Insights

None beyond the paper's own contributions. The core insight — that LLM annotation consistency can serve as a resolution selection criterion — is the paper's novel contribution. The reviews do not surface additional conceptual observations that the paper itself does not already contain.

## Suggestions

The paper's most urgent need is a quantitative validation of the Resolution Score against ground-truth biological groupings. Concretely: leverage the known perturbation targets in the K562 dataset to construct a "true" pathway partition, compute ARI/NMI between that partition and clusters at each resolution (0.3, 0.4, 0.5, etc.), and compare which resolution best recovers the known structure — both for HypoGeneAgent's choice and for the choices of silhouette, modularity, and enrichment. Include negative controls (shuffled data). This would turn the paper from a descriptive proof-of-concept into a validated method.

## Score and Decision

**Round 1 bracketing.** Three bands were queried on "LLM agent for gene set analysis single-cell clustering resolution": weak (avg ≤ 3.5, n=4), middle (3.5 < avg < 7.5, n=4), strong (avg ≥ 7.5, n=4). The weak band returned papers scoring 2.5–3.4 (e.g., scMPT at 3.4, rejected); the middle band returned papers scoring 4.25–5.8 (e.g., TAROT at 4.33, rejected; scDCA at 5.8, rejected); the strong band returned papers scoring 7.75+ (clearly different domain — LLM control/NLG papers). This placed the paper squarely in the middle band.

**Round 2 narrowing.** Two focused queries retrieved more anchors in the (3, 4.5) and (4, 6.5) ranges. Key comparisons:

- **vs scMPT (3.40)**: scMPT simply concatenated scGPT and GenePT embeddings with a dense layer — minimal technical contribution. HypoGeneAgent has a far more novel idea and stronger Stage 1 validation. HypoGeneAgent is clearly better.
- **vs TAROT (4.33)**: TAROT combined existing components (masked autoencoder + OT + splines) and had biological validation (gene knockout experiments, multiple benchmarks). HypoGeneAgent is more novel but less rigorously evaluated. Roughly comparable overall, with HypoGeneAgent slightly stronger on novelty and TAROT stronger on validation.
- **vs scDCA (5.80)**: scDCA had held-out evaluations, proper baselines (chemCPA, CPA), and quantitative comparisons. HypoGeneAgent lacks this rigor for its central claim. HypoGeneAgent is clearly weaker.
- **vs LLM-guided disease progression (3.75)**: Both have a creative LLM-in-the-loop idea but weak validation of the core claim. HypoGeneAgent has better Stage 1 validation (GOBP benchmarks) but similar evaluation gaps for the main contribution. HypoGeneAgent is slightly stronger.

**Final calibration.** The paper sits above scMPT (3.4) and the LLM-disease-progression paper (3.75), roughly on par with TAROT (4.33) in overall quality — but with a different profile: higher novelty, weaker evaluation. The central claim is unsupported by quantitative evidence against ground truth, which is a structural gap that prevents the paper from reaching the 5+ range. Score: **4.0**.

**Anchors retrieved:**

| Path | Avg Score | Round | Comparison |
|------|-----------|-------|------------|
| nUpM7egYFd.md (scMPT) | 3.40 | R1, R2 | Weaker contribution (concatenation of embeddings); HypoGeneAgent is more novel |
| 44IKUSdbUD.md | 3.00 | R1 | Different subfield (gene-gene interaction discovery); not directly comparable |
| TUUjIWntkU.md | 2.50 | R1 | Different domain (medical image clustering); not directly comparable |
| K1bv86Uvbp.md | 3.00 | R1 | Different domain (biomedical KG construction); not directly comparable |
| 5JXvgNCQUq.md (TAROT) | 4.33 | R1, R2 | Comparable quality; TAROT stronger on validation, HypoGeneAgent stronger on novelty |
| tKn6gpvlUX.md (scDCA) | 5.80 | R1 | Stronger evaluation methodology; HypoGeneAgent weaker on central claim validation |
| rSAPrQzoQa.md | 5.00 | R1 | Different domain (subject clustering with IF-PCA); not directly comparable |
| GXzwq6waYb.md | 4.25 | R2 | Different domain (hallucination detection); not directly comparable |
| Spp2i1hKwV.md (IDEAL) | 6.00 | R2 | Accepted poster; different domain (NLP selective annotation); stronger evaluation |
| mhyl7HhNM5.md | 6.33 | R2 | Different domain (label error detection); not directly comparable |
| UTP6bdFlkB.md | 3.75 | R2 | Similar weakness profile (LLM-in-the-loop with insufficient validation); HypoGeneAgent slightly stronger |

**Round 1 bracket**: 3.5–7.5 (middle band).  
**Round 2 narrowing**: 3.75–4.33, with the paper settling at 4.0 based on the comparison with TAROT (4.33) and scMPT (3.40).

MY FINAL SCORE: <score>4.0</score>
MY FINAL DECISION: <decision>Reject</decision>